CRISPR Therapeutics' (CRSP) "Market Outperform" Rating Reaffirmed at JMP Securities

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report)'s stock had its "market outperform" rating restated by analysts at JMP Securities in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $86.00 price target on the stock. JMP Securities' price target indicates a potential upside of 119.11% from the stock's current price.

A number of other research analysts have also weighed in on the company. Stifel Nicolaus decreased their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating on the stock in a report on Thursday, February 13th. Needham & Company LLC reiterated a "buy" rating and issued a $81.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday. Chardan Capital decreased their target price on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Evercore ISI upgraded CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and upped their price objective for the stock from $60.00 to $99.00 in a research report on Friday, February 14th. Finally, Morgan Stanley raised their target price on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the company an "underweight" rating in a research report on Friday, February 14th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of "Hold" and an average price target of $71.75.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock opened at $39.25 on Wednesday. CRISPR Therapeutics has a 52-week low of $30.04 and a 52-week high of $67.88. The firm has a market cap of $3.39 billion, a PE ratio of -8.98 and a beta of 1.88. The business's 50 day simple moving average is $37.34 and its 200 day simple moving average is $42.22.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same period in the prior year, the business posted ($1.43) EPS. The firm's quarterly revenue was up 71.6% on a year-over-year basis. As a group, equities research analysts predict that CRISPR Therapeutics will post -5.16 EPS for the current year.

Insider Activity

In other news, Director John Greene acquired 7,000 shares of the stock in a transaction that occurred on Wednesday, February 26th. The shares were acquired at an average cost of $44.85 per share, for a total transaction of $313,950.00. Following the purchase, the director now owns 7,000 shares of the company's stock, valued at approximately $313,950. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 9,973 shares of the firm's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $423,054.66. Following the completion of the transaction, the chief executive officer now directly owns 180,890 shares of the company's stock, valued at $7,673,353.80. The trade was a 5.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,021 shares of company stock worth $594,771 over the last quarter. 4.30% of the stock is currently owned by corporate insiders.

Institutional Trading of CRISPR Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Intellectus Partners LLC lifted its position in CRISPR Therapeutics by 3.6% during the fourth quarter. Intellectus Partners LLC now owns 7,131 shares of the company's stock valued at $281,000 after purchasing an additional 250 shares during the last quarter. Farrow Financial Inc. raised its holdings in shares of CRISPR Therapeutics by 1.4% during the 4th quarter. Farrow Financial Inc. now owns 20,097 shares of the company's stock valued at $777,000 after buying an additional 270 shares in the last quarter. Kestra Private Wealth Services LLC raised its holdings in shares of CRISPR Therapeutics by 1.5% during the 4th quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company's stock valued at $812,000 after buying an additional 310 shares in the last quarter. SFE Investment Counsel lifted its position in CRISPR Therapeutics by 5.8% in the 1st quarter. SFE Investment Counsel now owns 6,507 shares of the company's stock worth $221,000 after buying an additional 355 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in CRISPR Therapeutics by 7.6% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company's stock worth $215,000 after buying an additional 372 shares in the last quarter. Institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.